FDA
approval
· 2022-04-29
FDA Approved: BRIELLYN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
Summary
FDA approved a supplemental application for BRIELLYN, a generic combined oral contraceptive containing norethindrone and ethinyl estradiol, developed by Glenmar…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for BRIELLYN (NORETHINDRONE AND ETHINYL ESTRADIOL)